A blood test that measures the number of circulating tumor cells (CTCs) at the time of metastatic prostate cancer diagnosis can predict treatment response, disease progression, and overall survival, regardless of subsequent therapies over time, shows a study led by University of Southern California (USC) researchers. View full article here.
